A1C

New Data Shows Virta Health Closes Gaps in Diabetes Care for Underserved Populations

Retrieved on: 
Lundi, juin 26, 2023
Health, Diabetes, Amputation, Insulin, National Medical Association, Eye, Health equity, Research, Multimedia, Hypoglycemia, Deprescribing, Patient, Risk, Navy, American Diabetes Association, ADI, Kidney, Death, Family, African Americans, Pharmaceutical industry, Medical device, A1C

Virta Health, the leader in type 2 diabetes reversal, released real-world data at the American Diabetes Association’s 83rd Scientific Sessions demonstrating how its approach is narrowing gaps in care.

Key Points: 
  • Virta Health, the leader in type 2 diabetes reversal, released real-world data at the American Diabetes Association’s 83rd Scientific Sessions demonstrating how its approach is narrowing gaps in care.
  • New research shows that Virta’s approach can narrow these gaps by helping members achieve better metabolic health while reducing or even eliminating the need for medications like insulin.
  • Yet, at one year, all members saw significant health improvement and medication deprescription with Virta’s diabetes reversal approach, regardless of neighborhood socioeconomic conditions.
  • Through modifying my lifestyle with Virta, along with many of my favorite Caribbean recipes, I’ve now reversed my diabetes, lost over 20 pounds, and regained my energy.

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

Retrieved on: 
Samedi, juin 24, 2023
Real-World Evidence, Hyperglycemia, Diabetes, AIT, Meal, Doctor of Philosophy, A1C, TIR, Medtronic, MD, Collection, Patient, SAN, Forgiveness, American Diabetes Association, ADA, NYSE, Dietary supplement, Medical device

Additionally, the system is helping reduce the percent of time spent in hyperglycemia in children and adults.

Key Points: 
  • Additionally, the system is helping reduce the percent of time spent in hyperglycemia in children and adults.
  • These latest results were presented this weekend at the 83rd American Diabetes Association (ADA) Scientific Sessions in San Diego, CA.
  • "This study shows that a simplified meal management approach with the MiniMed™ 780G system helped users maintain glycemic targets while providing forgiveness for inexact carb counts.
  • Clearly there's more runway for simplification of diabetes management with this system and it's promising for the many patients struggling with meal management."

MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)

Retrieved on: 
Jeudi, juin 22, 2023
AID, Insulin, Mayo Clinic, Doctor of Pharmacy, University, MDI, T1D, Teaching, Joslin Diabetes Center, A1C, Patient, University of Washington School of Medicine, Randomized controlled trial, Diabetes, MannKind Corporation, Automation, Pharmaceutical industry, Northwestern University, Medicine

“This large study is planned to assess improvement in mealtime glycemic control, which continues to be a serious challenge for the majority of people living with type 1 diabetes,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation.

Key Points: 
  • “This large study is planned to assess improvement in mealtime glycemic control, which continues to be a serious challenge for the majority of people living with type 1 diabetes,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation.
  • Both arms will utilize continuous glucose monitoring to assess mealtime control and A1c levels.
  • “People living with diabetes deserve options and innovation that can reduce burdens and provide impactful glucose control,” said Dr. Irl B. Hirsch, Professor of Medicine and Diabetes Treatment and Teaching Chair at the University of Washington.
  • For more information on INHALE-3 and the list of participating sites, please visit: https://clinicaltrials.gov/ct2/show/NCT05904743 .

US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older

Retrieved on: 
Mercredi, juin 21, 2023
Hypersensitivity, Exercise, Insulin, Diet, Prevalence, Medicine, Type 2 diabetes, Diabetes, Diabetic ketoacidosis, Angioedema, Dialysis, Tablet, Boehringer Ingelheim, A1C, Excipient, LLY, Hypoglycemia, Lilly, Patient, Metformin, Risk, Eli Lilly and Company, Ageing, Regulatory affairs, FDA, Safety, III, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical device, F.A.C.E

RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.

Key Points: 
  • Jardiance is not recommended in patients with type 1 diabetes.
  • Jardiance is not recommended for use to improve glycemic control in patients with type 2 diabetes with an eGFR less than 30 mL/min/1.73 m2.
  • Type 2 diabetes represents a significant and growing health concern among young people in the U.S. Over the past two decades, the prevalence of type 2 diabetes in people aged 10-19 has nearly doubled.
  • New treatment options are critical to help address the over 5,700 new cases of type 2 diabetes in this population each year in the U.S.

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

Retrieved on: 
Mercredi, juin 21, 2023
ENDO, Rat, FISU World University Games, Pain, Graves' ophthalmopathy, A1C, Patient, Hypercalcaemia, Primary hyperparathyroidism, SST2, Health, Hyperthyroidism, Memory, PTH1R, Fatigue, Thyroid, Camp, PRO, Weakness, HHM, Acromegaly, Headache, Safety, Growth hormone, Cancer, Medicine, Biomarker, History, Calcium, ASD, Swelling, Autoimmune disease, Endocrine Society, Perspiration, Medical school, Human, Blood pressure, Exophthalmos, TSH, Malignancy, Osteoporosis, Endocrine system, Arthralgia, Sequoyah, Saint Andrew's Society, PHPT, Poster, TSHR, TED, Pharmaceutical industry, Entrepreneurship, Endocrinology

SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented efficacy, safety and patient-reported outcome (PRO) data at ENDO 2023 for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for the treatment of acromegaly. The Endocrine Society’s annual meeting, ENDO 2023, was held June 15-18, 2023, in Chicago, Illinois.

Key Points: 
  • The Endocrine Society’s annual meeting, ENDO 2023 , was held June 15-18, 2023, in Chicago, Illinois.
  • The ASD score was a composite representing participants’ daily impressions of common acromegaly symptoms including headache, joint pain, sweating, fatigue, weakness, swelling, and numbness/tingling.
  • Approximately 90% of participants said they preferred once-daily, oral paltusotine over current standard of care of injected SRLs when asked after one year of treatment.
  • The data presented in a poster at ENDO on June 17th show Crinetics’ PTH1R antagonist suppressing PTH-stimulated increases in ionized calcium, urinary cAMP, and bone resorption biomarkers in rats.

Cardio Diagnostics Publishes Research Highlighting the Reversibility of Epigenetic Signatures of Coronary Heart Disease

Retrieved on: 
Mardi, juin 13, 2023
Health, Technology, Health Technology, Research, Artificial Intelligence, Science, Cardiology, DNA, Radiation, Methylation, Diabetes, Single-nucleotide polymorphism, Moyamoya disease, Coronary artery disease, Kidney, A1C, Cardio, Risk, Smoke, Gene, Lipid metabolism, DNA methylation, Smoking cessation, Death, Smoking, CHD, PCR, Glycated hemoglobin, Pharmaceutical industry, Medical imaging

The study titled "The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation" sheds light on the potential of reversing epigenetic changes associated with coronary heart disease (CHD) through smoking cessation.

Key Points: 
  • The study titled "The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation" sheds light on the potential of reversing epigenetic changes associated with coronary heart disease (CHD) through smoking cessation.
  • This new study represents a breakthrough in understanding the potential for reversing epigenetic changes associated with coronary heart disease.
  • Meesha Dogan, Ph.D., CEO and co-founder of Cardio Diagnostics and one of the study's authors, remarked, "Our research represents a substantial advancement in the field of coronary heart disease management.
  • This groundbreaking research marks a significant advancement in understanding and managing coronary heart disease and showcases the potential of integrating AI-driven diagnostics in precision cardiovascular medicine.

Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions

Retrieved on: 
Lundi, juin 12, 2023
CGM, University Children's Hospital Basel, MBA, Doctor of Philosophy, A1C, Metabolism, MD, Patient, Medtronic, Ageing, R, Randomized controlled trial, American Diabetes Association, ADA, NYSE, Diabetes, Research, SR, Glucose meter, Spinal cord stimulator, Hospital, FDA, Adaptive Deep Brain Stimulation, Insulin, Endocrinology, FOH, MDI, T1D, PDT, Cincinnati Children's Hospital Medical Center, Singapore General Hospital, Children's Hospital & Medical Center, MPH, Real Life, Trial of the century, System Settings, ADAPT, SIP, Poster, Pharmaceutical industry, Birth control, Health insurance, Nursing, Management, Brain, Carbohydrate

DUBLIN, June 12, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in medical technology, today announced its participation in the upcoming American Diabetes Association's (ADA) 83rd Scientific Sessions in San Diego on Jun.

Key Points: 
  • DUBLIN, June 12, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in medical technology, today announced its participation in the upcoming American Diabetes Association's (ADA) 83rd Scientific Sessions in San Diego on Jun.
  • The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research.
  • Poster presentations will be available to all attendees for viewing throughout the conference.
  • 26 at 11:30 a.m. PDT
    "Real-World Clinical Data on the Extended Infusion Set" – poster presentation (910-P) by Tim Kwa, senior product engineer, Medtronic on Sunday, Jun.

NEW STUDY FINDS THAT FITTERFLY DIABETES DIGITAL THERAPEUTICS PROGRAM IMPROVES BLOOD SUGAR LEVELS AND PROMOTES WEIGHT LOSS IN PATIENTS WITH TYPE 2 DIABETES

Retrieved on: 
Mardi, mai 9, 2023
CGM, Exercise, Weight, Therapy, Diabetes, A1C, Physician, Nutritionist, Health, Human, Glycated hemoglobin, Medical device

The study led by Shilpa Joshi, Arbinder Singal, and colleagues found significant improvements in both blood glucose levels and weight management in participants enrolled in the 90-day program.

Key Points: 
  • The study led by Shilpa Joshi, Arbinder Singal, and colleagues found significant improvements in both blood glucose levels and weight management in participants enrolled in the 90-day program.
  • This study analyzed de-identified data of 109 participants with type 2 diabetes.
  • Dr Arbinder Singal, CEO and cofounder of Fitterfly, said, "Type 2 diabetes is a huge health care concern in India.
  • Thus, Fitterfly's CGM program could be a valuable tool for health care professionals in managing type 2 diabetes and supporting weight loss goals.

FTC to companies making questionable diabetes claims: Cease and desist now

Retrieved on: 
Dimanche, avril 23, 2023
Insulin, Federal Trade Commission Act of 1914, Diabetes, Friends, United States district court, The Nader Report on the Federal Trade Commission, Policy, Prescription, Record, Blog, Privacy, Federal Trade Commission, CDC, A1C, Plant, Blood, Patient, Risk, FTC, Comment, Seizure, Fraud, FDA, Social media, Disease, Dietary supplement

FTC to companies making questionable diabetes claims: Cease and desist now

Key Points: 

FTC to companies making questionable diabetes claims: Cease and desist now

Digital Diagnostics Expands to Lab Settings Increasing Access to Care

Retrieved on: 
Vendredi, avril 21, 2023
De novo, Diabetes, Paratriathlon, A1C, AL, Patient, Physician, Artificial intelligence, Diabetic retinopathy, Diagnosis, PSC, Health, FDA, Labcorp, Disease, Medical device, Nursing, Southeast Division

CORALVILLE, Iowa, April 21, 2023 /PRNewswire/ -- Digital Diagnostics, a leading artificial intelligence diagnostic health care company, announced its expansion into lab settings in the southeast region of the United States. The company's flagship product, LumineticsCore™ formerly IDx-DR, is now available in nine Labcorp patient service centers (PSCs) in Alabama providing access to care for people with diabetes through the initial market launch of the De Novo FDA-cleared autonomous artificial intelligence diagnostic system. LumineticsCore is FDA cleared to detect diabetic retinopathy during a patient encounter by analyzing retinal images for signs of disease without the need for a specialist to interpret the images.

Key Points: 
  • CORALVILLE, Iowa, April 21, 2023 /PRNewswire/ -- Digital Diagnostics, a leading artificial intelligence diagnostic health care company, announced its expansion into lab settings in the southeast region of the United States.
  • In collaboration with Labcorp, they have launched diabetic retinopathy exams at Labcorp PSCs in Alabama, improving access and reducing a gap in care for many patients and providers.
  • "We are always seeking innovative ways to bring convenient care to our patients and providers," said Lenny Monsour, senior vice president of Labcorp Diagnostic's Southeast Division.
  • "Working with Digital Diagnostics allows us to offer an expanded set of services to our patients, while empowering our providers with more ways to serve the health care needs of their local communities."